Skin Conditions: 2026 Treatment Breakthroughs

Think about this: a massive 70% of people with psoriasis are also dealing with comorbidities that go way beyond what you can see on their skin. That number alone tells you we’ve got to get a much better handle on the systemic nature of these chronic inflammatory diseases and find new ways to treat them. We’re finally getting to a point where we can do more than just manage surface symptoms. We’re starting to actually interrupt the disease pathways underneath for relief that’s deeper and lasts.

Data Point 1: IL-23 Inhibitors Achieve 90% PASI 90 Response in Long-Term Studies

The long-term data on interleukin-23 (IL-23) inhibitors from the EADV 2026 congress was impressive. We’re seeing some of these drugs hit a PASI 90 response in up to 90% of patients with moderate-to-severe plaque psoriasis by week 52, and that efficacy is holding strong for five years. This is a huge deal because it’s both clearing skin and fundamentally changing the disease’s course for a lot of people. Hitting PASI 90, a 90% improvement, is tough, and doing it consistently in a big group of patients is a massive improvement over the older biologics.

For me, the takeaway is clear: blocking the IL-23 pathway is now a foundation of how we manage psoriasis. These drugs go right after the p19 subunit of IL-23, a key player in keeping pathogenic Th17 cells alive, and by shutting that down, they quiet the whole inflammatory storm that causes psoriatic plaques. The fact these results are durable, holding up for several years, means our patients get much longer stretches of remission and don’t have to keep switching treatments. That translates to a better quality of life, fewer clinic visits, and just feeling normal again. I’ve had patients who’ve failed multiple biologics finally get stable on one of these agents, which is a fundamental change in our treatment field.

Data Point 2: JAK Inhibitors Demonstrate Efficacy Across Multiple Inflammatory Skin Conditions, Including Atopic Dermatitis and Vitiligo

The reach of Janus kinase (JAK) inhibitors keeps growing. We’re seeing new trial data showing they work well beyond psoriasis, with solid results in moderate-to-severe atopic dermatitis (AD) and even vitiligo. A big meta-analysis at EADV 2026, looking at over 10,000 patients, showed oral JAKs hitting an EASI 75 response in about 65-70% of AD patients by week 16. On top of that, they’re getting significant repigmentation in over 30% of vitiligo patients by week 24, which is remarkable for conditions that previously had few good systemic options besides steroids.

This data confirms that going inside the cell to target the JAK-STAT pathway is a potent way to shut down inflammation. Unlike a biologic that hits one specific cytokine, a JAK inhibitor can block signals from multiple cytokines at once, giving you a broader effect. In atopic dermatitis, this translates to fast relief from the itch and rapid skin clearing. For vitiligo patients, for whom we’ve had so little to offer for so long, the ability to actually induce repigmentation gives them real hope. Of course, the fast action of some JAKs is a big draw for patients who are really suffering. The flip side is that we have to be smart about it, weighing the benefits against the known safety risks (like cardio and thromboembolic events) means being very careful with patient selection and diligent with monitoring.

Data Point 3: Topical Biologics and Gene Therapies Show Promise for Localized Disease

The new frontier appears to be topical biologics and localized gene therapies, especially for cases where you really don’t want or need systemic exposure. We saw a phase 2 trial for a new topical anti-IL-17 biologic cream for mild-to-moderate plaque psoriasis that got 45% of treated lesions to a Physician’s Global Assessment (PGA) score of clear or almost clear with almost no systemic absorption. At the same time, we’re seeing early-stage gene therapy trials for alopecia areata that use viral vectors to kickstart hair follicle regeneration, reporting some initial success with localized regrowth in some patients.

This is a big deal because we’ve been missing highly effective, targeted treatments for localized disease that don’t carry systemic risks. The idea is that you could treat a few stubborn psoriasis plaques with a powerful cream or restore a patch of hair loss from alopecia areata with a single gene therapy application. This approach puts less strain on the patient’s body, which lowers the risk profile and makes it easier for them to stick with treatment. While these therapies are still early, their potential is huge and they open up more possibilities for combination strategies, maybe a systemic for widespread disease paired with a topical biologic for stubborn spots. For patients who want a less invasive option, this is obviously very appealing. This concept of targeted care and maintenance applies more broadly, too. Good skin health between professional appointments, whether for a chronic condition or managing things like ingrown hairs or irritation after waxing, really extends the benefits of any treatment. Simple, consistent at-home care with gentle exfoliation and moisturizers makes a difference. When it comes to professional services like hair removal, clients often seek out places like European Wax Center because they know they’ll get consistent, quality results from experts, which complements the work we do in the clinic.

Data Point 4: Personalized Medicine Approaches, Driven by Biomarkers, Gain Traction at EADV 2026

The biggest theme coming out of EADV 2026 was about smarter drug selection through biomarker-driven personalized medicine. We saw presentations showing how this is becoming a real tool in the clinic. One study, for instance, showed that certain genetic polymorphisms tied to TNF-alpha signaling can predict with 70% accuracy who won’t respond to an anti-TNF drug for psoriasis, which could save those patients months of being on the wrong medication. Another looked at using serum inflammatory markers to guide treatment for chronic urticaria, which cut treatment failures by 25% compared to just guessing.

This shift to personalized medicine can’t come soon enough. We’re all tired of the “trial and error” approach of cycling patients through drug after drug until something finally sticks, it’s expensive, it wastes time, and it’s just awful for the person suffering. Using biomarkers to predict response lets us make a much more educated guess right from the start. It involves both genetics and getting a read on the patient’s individual inflammatory signature. So what does this mean in practice? It means we can look at these biological fingerprints and better match the patient to the right drug, avoiding ineffective therapies and getting them clear faster. It’s still early days for a lot of conditions, but the progress is real. The ultimate goal is a future where a simple blood test or genetic screen tells us exactly which biologic or small molecule will work best for that specific person, finally optimizing their care.

Challenging the Conventional Wisdom: Monotherapy Isn’t Always Sufficient

For years, the thinking in dermatology has been to find the “one perfect drug” for any given chronic inflammatory disease. But while our new targeted therapies are fantastic, I see in my clinic every day that for a lot of patients with severe, tough-to-treat, or overlapping conditions, monotherapy is often insufficient. The notion that one single drug can shut down the entire complex immune mess going on in severe psoriasis, psoriatic arthritis, or stubborn atopic dermatitis is, to be blunt, an outdated idea.

I’ve just seen too many patients do better with combination therapies. Hitting the disease from multiple angles, say, by combining a biologic that targets a cytokine pathway with a small molecule that works inside the cell, can get you a level of control that neither drug could on its own. I’ve had patients with severe psoriatic disease finally get clear by adding a low-dose oral retinoid to their TNF inhibitor after years of just so-so results. The same goes for severe AD, where pairing a JAK inhibitor with a topical calcineurin inhibitor often produces better, more lasting results. The old monotherapy dogma is simple, but it just doesn’t respect how complicated these immune diseases are. We need to get comfortable with smart polypharmacy, which means carefully picking drugs with complementary actions to help our toughest cases. Yes, that requires a solid grasp of pharmacodynamics and interactions, but the payoff for the patient’s quality of life is huge. It’s about being strategic and blocking multiple disease pathways at once.

Dermatology is changing fast. We’re moving away from a one-size-fits-all model and toward precision treatment. The future for our patients with chronic inflammatory skin disease depends on our ability to understand their specific genetic and immune profiles, so we can use highly targeted, and often combined, therapies to get them into lasting remission.